What I'm buying, Simavita Ltd (SVA). Medical Device Company that has developed an innovative solution for the assessment of urinary Incontinence, with a focus on the elderly. Currently there are 15 million plus incontinence assessments per year that result in $6 billion of labour costs. SIM is a wireless sensor technology which delivers instrumented Incontinence Assessments that result in 25% product cost reduction, 23% decrease in landfill and 21% improvement in effective toileting. I attended a management presentation earlier this week and was very impressed with CEO Philippa Lewis who has 25 years in the industry. Currently supplying their technology to $7bn firm Medline, which is the leading provider of adult incontinence products to the US healthcare market, you can be sure traction is imminent. The company expects global revenue to commence this quarter out of the US which will be a significant catalyst. CP $0.90, TP $1.09
Enjoyed your write up on Peter Birtles this morning Dean. Simavita is one that Alex Cowie has followed a little, I suspect he will have more to add on this front.
Thanks James, I've always put a great deal of emphasis on strong management when making investment decisions.
Alex, couldn't agree more, revenue rolling in this year, 1100 medline sales reps to leverage off and an ageing population. It's got a bright future.
A lot to like about small-cap medical device stock with proven tech, and a US distribution deal. A rare opportunity on the ASX to leverage the global ageing demographic thematic. Good call Dean.